Overview Dividends

(USNA) USANA Health Sciences - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US90328M1071

Vitamins, Supplements, Skincare, Meal Shakes, Snack Bars

Personal Care Products
Market Cap in USD: 358m

IPO / Inception: 1996-07-25
Return 12m vs S&P 500: -52.8%

EPS (Earnings per Share)

EPS CAGR: -52.67%
EPS Trend: -67.6%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: -5.80%
Rev. Trend: -64.3%

Last SUE: -0.03
Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	38.7%
Value at Risk 5%th	56.3%
Relative Tail Risk	-11.41%

Reward TTM
Sharpe Ratio	-1.15
Alpha	-59.62
CAGR/Max DD	-0.40

Character TTM
Hurst Exponent	0.372
Beta	0.801
Beta Downside	0.935

Drawdowns 3y
Max DD	72.51%
Mean DD	35.08%
Median DD	34.53%

Description: USNA USANA Health Sciences December 26, 2025

USANA Health Sciences (NYSE:USNA) designs, manufactures, and markets science-based nutritional, personal-care, and skincare products across the Asia-Pacific, Americas, and Europe, operating through a Direct-Selling segment and a Hiya Direct-to-Consumer (DTC) segment.

Its core portfolio includes USANA Optimizers (cardiovascular, skeletal, and digestive health), Essentials/CellSentials (vitamins and minerals for children 13 months onward), and food items such as meal-replacement shakes and snack bars. The company also sells Celavive skincare, and provides online tools and materials to support its independent associate network. Sales channels combine retail, subscription, direct-selling, and e-commerce platforms.

Recent performance shows FY2023 revenue of roughly $2.5 billion, with the Direct-Selling segment contributing about 70 % of total sales and a 5 % year-over-year growth in DTC subscriptions-reflecting broader consumer shifts toward online health-product purchasing. Key economic drivers include rising global demand for preventive health supplements, an aging demographic in core markets, and expanding middle-class consumption in Asia-Pacific. USANA’s research partnership with Beijing University of Chinese Medicine and the National Sports Training Bureau underscores its focus on product innovation and credibility.

For a deeper quantitative assessment of USANA’s valuation dynamics, you may find ValueRay’s analytical tools useful.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income (17.0m TTM) > 0 and > 6% of Revenue (6% = 54.8m TTM)

FCFTA 0.03 (>2.0%) and ΔFCFTA -7.20pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 15.93% (prev 39.03%; Δ -23.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.04 (>3.0%) and CFO 31.5m > Net Income 17.0m (YES >=105%, WARN >=100%)

Net Debt (-145.3m) to EBITDA (83.9m) ratio: -1.73 <= 3.0 (WARN <= 3.5)

Current Ratio 2.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (18.3m) change vs 12m ago -4.14% (target <= -2.0% for YES)

Gross Margin 79.18% (prev 80.86%; Δ -1.68pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 130.6% (prev 128.4%; Δ 2.18pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 57.34 (EBITDA TTM 83.9m / Interest Expense TTM 848.0k) >= 6 (WARN >= 3)

Altman Z'' 7.12

(A) 0.20 = (Total Current Assets 264.1m - Total Current Liabilities 118.7m) / Total Assets 726.6m

(B) 0.64 = Retained Earnings (Balance) 467.5m / Total Assets 726.6m

(D) 3.09 = Book Value of Equity 448.2m / Total Liabilities 145.0m

Total Rating: 7.12 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 56.31

1. Piotroski 7.0pt

2. FCF Yield 7.41%

3. FCF Margin 2.05%

4. Debt/Equity 0.07

5. Debt/Ebitda -1.73

6. ROIC - WACC (= 2.43)%

7. RoE 3.21%

8. Rev. Trend -64.29%

9. EPS Trend -67.65%

What is the price of USNA shares?

As of December 30, 2025, the stock is trading at USD 19.73 with a total of 92,817 shares traded.
Over the past week, the price has changed by +0.20%, over one month by +0.66%, over three months by -28.67% and over the past year by -44.09%.

Is USNA a buy, sell or hold?

USANA Health Sciences has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold USNA.

Strong Buy: 0
Buy: 0
Hold: 1
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the USNA price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	39	97.7%
Analysts Target Price	39	97.7%
ValueRay Target Price	14.2	-27.9%

USNA Fundamental Data Overview December 25, 2025

Market Cap USD = 358.3m (358.3m USD * 1.0 USD.USD)
P/E Trailing = 21.7778
P/E Forward = 11.919
P/S = 0.3926
P/B = 0.6816
P/EG = 0.9381
Beta = 0.652
Revenue TTM = 912.7m USD
EBIT TTM = 48.6m USD
EBITDA TTM = 83.9m USD
Long Term Debt = 6.01m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 29.0m USD (from shortTermDebt, last fiscal year)
Debt = 39.2m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -145.3m USD (from netDebt column, last quarter)
Enterprise Value = 252.2m USD (358.3m + Debt 39.2m - CCE 145.3m)
Interest Coverage Ratio = 57.34 (Ebit TTM 48.6m / Interest Expense TTM 848.0k)
FCF Yield = 7.41% (FCF TTM 18.7m / Enterprise Value 252.2m)
FCF Margin = 2.05% (FCF TTM 18.7m / Revenue TTM 912.7m)
Net Margin = 1.86% (Net Income TTM 17.0m / Revenue TTM 912.7m)
Gross Margin = 79.18% ((Revenue TTM 912.7m - Cost of Revenue TTM 190.0m) / Revenue TTM)
Gross Margin QoQ = 77.15% (prev 78.72%)
Tobins Q-Ratio = 0.35 (Enterprise Value 252.2m / Total Assets 726.6m)
Interest Expense / Debt = 0.12% (Interest Expense 49.0k / Debt 39.2m)
Taxrate = 471.3% (out of range, set to none) (8.46m / 1.79m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 2.23 (Total Current Assets 264.1m / Total Current Liabilities 118.7m)
Debt / Equity = 0.07 (Debt 39.2m / totalStockholderEquity, last quarter 528.1m)
Debt / EBITDA = -1.73 (Net Debt -145.3m / EBITDA 83.9m)
Debt / FCF = -7.78 (Net Debt -145.3m / FCF TTM 18.7m)
Total Stockholder Equity = 530.3m (last 4 quarters mean from totalStockholderEquity)
RoA = 2.34% (Net Income 17.0m / Total Assets 726.6m)
RoE = 3.21% (Net Income TTM 17.0m / Total Stockholder Equity 530.3m)
RoCE = 9.07% (EBIT 48.6m / Capital Employed (Equity 530.3m + L.T.Debt 6.01m))
RoIC = 10.51% (EBIT 48.6m / (Assets 726.6m - Curr.Liab 118.7m - Cash 145.3m))
WACC = 8.09% (E(358.3m)/V(397.5m) * Re(8.97%) + (debt cost/tax rate unavailable))
Discount Rate = 8.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.52%
[DCF Debug] Terminal Value 72.50% ; FCFE base≈37.5m ; Y1≈32.6m ; Y5≈26.1m
Fair Price DCF = 22.11 (DCF Value 404.1m / Shares Outstanding 18.3m; 5y FCF grow -16.00% → 3.0% )
EPS Correlation: -67.65 | EPS CAGR: -52.67% | SUE: -4.0 | # QB: 0
Revenue Correlation: -64.29 | Revenue CAGR: -5.80% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.40 | Chg30d=-0.040 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=1.90 | Chg30d=-0.200 | Revisions Net=-1 | Growth EPS=+9.8% | Growth Revenue=-1.6%

Additional Sources for USNA Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle